Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- PMID: 19269895
- DOI: 10.1016/S1470-2045(09)70025-7
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Abstract
Background: In 2004, a randomised phase III trial by the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NCIC) reported improved median and 2-year survival for patients with glioblastoma treated with concomitant and adjuvant temozolomide and radiotherapy. We report the final results with a median follow-up of more than 5 years.
Methods: Adult patients with newly diagnosed glioblastoma were randomly assigned to receive either standard radiotherapy or identical radiotherapy with concomitant temozolomide followed by up to six cycles of adjuvant temozolomide. The methylation status of the methyl-guanine methyl transferase gene, MGMT, was determined retrospectively from the tumour tissue of 206 patients. The primary endpoint was overall survival. Analyses were by intention to treat. This trial is registered with Clinicaltrials.gov, number NCT00006353.
Findings: Between Aug 17, 2000, and March 22, 2002, 573 patients were assigned to treatment. 278 (97%) of 286 patients in the radiotherapy alone group and 254 (89%) of 287 in the combined-treatment group died during 5 years of follow-up. Overall survival was 27.2% (95% CI 22.2-32.5) at 2 years, 16.0% (12.0-20.6) at 3 years, 12.1% (8.5-16.4) at 4 years, and 9.8% (6.4-14.0) at 5 years with temozolomide, versus 10.9% (7.6-14.8), 4.4% (2.4-7.2), 3.0% (1.4-5.7), and 1.9% (0.6-4.4) with radiotherapy alone (hazard ratio 0.6, 95% CI 0.5-0.7; p<0.0001). A benefit of combined therapy was recorded in all clinical prognostic subgroups, including patients aged 60-70 years. Methylation of the MGMT promoter was the strongest predictor for outcome and benefit from temozolomide chemotherapy.
Interpretation: Benefits of adjuvant temozolomide with radiotherapy lasted throughout 5 years of follow-up. A few patients in favourable prognostic categories survive longer than 5 years. MGMT methylation status identifies patients most likely to benefit from the addition of temozolomide.
Funding: EORTC, NCIC, Nélia and Amadeo Barletta Foundation, Schering-Plough.
Comment in
-
A silver lining on the horizon for glioblastoma.Lancet Oncol. 2009 May;10(5):434-5. doi: 10.1016/S1470-2045(09)70124-X. Lancet Oncol. 2009. PMID: 19410186 No abstract available.
Similar articles
-
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.Lancet Oncol. 2008 Jan;9(1):29-38. doi: 10.1016/S1470-2045(07)70384-4. Epub 2007 Dec 21. Lancet Oncol. 2008. PMID: 18082451 Clinical Trial.
-
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.Lancet Oncol. 2012 Jul;13(7):707-15. doi: 10.1016/S1470-2045(12)70164-X. Epub 2012 May 10. Lancet Oncol. 2012. PMID: 22578793 Clinical Trial.
-
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.Lancet Oncol. 2014 Sep;15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1. Epub 2014 Aug 19. Lancet Oncol. 2014. PMID: 25163906 Clinical Trial.
-
[Standards and new developments in the chemotherapy of glioblastomas].Dtsch Med Wochenschr. 2005 Oct 7;130(40):2270-4. doi: 10.1055/s-2005-918562. Dtsch Med Wochenschr. 2005. PMID: 16208603 Review. German.
-
Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis.JAMA Neurol. 2015 May;72(5):589-96. doi: 10.1001/jamaneurol.2014.3739. JAMA Neurol. 2015. PMID: 25822375 Review.
Cited by
-
The Role of Systemic Therapies in the Treatment of Grades 1-4 Gliomas.Cureus. 2024 Sep 30;16(9):e70532. doi: 10.7759/cureus.70532. eCollection 2024 Sep. Cureus. 2024. PMID: 39439623 Free PMC article. Review.
-
Optic Nerve Glioblastoma with Optic Chiasm Involvement: A Case Report and a Brief Literature Review.Medicina (Kaunas). 2024 Oct 14;60(10):1687. doi: 10.3390/medicina60101687. Medicina (Kaunas). 2024. PMID: 39459474 Free PMC article. Review.
-
Is Carmustine Wafer Implantation in Progressive High-Grade Gliomas a Relevant Therapeutic Option? Complication Rate, Predictors of Complications and Onco-Functional Outcomes in a Series of 53 Cases.Cancers (Basel). 2024 Oct 12;16(20):3465. doi: 10.3390/cancers16203465. Cancers (Basel). 2024. PMID: 39456559 Free PMC article.
-
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors.Semin Cancer Biol. 2022 Jul;82:162-175. doi: 10.1016/j.semcancer.2021.02.014. Epub 2021 Feb 25. Semin Cancer Biol. 2022. PMID: 33640445 Free PMC article. Review.
-
Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.Cochrane Database Syst Rev. 2021 Mar 12;3(3):CD013316. doi: 10.1002/14651858.CD013316.pub2. Cochrane Database Syst Rev. 2021. PMID: 33710615 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials